GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS ... in ongoing clinical trials including albiglutide, semaglutide, dulaglutide and ITCA650. Published and preliminary data have shown ...

LANGHORNE, PA — Amplity Health shared valuable findings from its latest study on GLP-1 receptor agonist ... for four GLP-1 RAs—liraglutide, dulaglutide, semaglutide, and exenatide—across ...

Not long after the FDA wrapped its preliminary investigation of GLP-1 receptor agonists and suicidal thoughts or actions, the ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor ... GLP-1 agonist liraglutide in people ...

Anti-obesity medication use was associated with reduced alcohol consumption among patients in a telehealth medical weight ...

Semaglutide and liraglutide also linked to reduction ... to AUD is decreased during use of glucagon-like peptide-1 (GLP-1) receptor agonists versus nonuse in the same individual.

Common medications within this class include: Semaglutide (Ozempic, Wegovy); Liraglutide ... for employers. 1. Cost. Today, glucagon like peptide-1 receptor agonists (GLP-1s) for weight loss ...